BioSpace News Archive

Compass Therapeutics announced the publication of extensive data demonstrating the preclinical efficacy and safety of the company’s lead investigational therapy, CTX-471, which is currently being evaluated in a Phase 1 clinical trial.

Ahead of Emergency Use Authorization and in accordance with the U.S. Food and Drug Administration Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency guidance document issued on March 16, 2020, Vela Diagnostics will offer the manual ViroKey™ SARS-CoV-2 RT-PCR Test when validation is completed.

In accordance with its new strategic direction “From Things to Life,” Dassault Systèmes announced that it is working with China’s Central-South Architectural Design Institute to support the simulation and evaluation of virus dispersal in the confined environment of Leishenshan Hospital in Wuhan, China.

Isofol Medical AB, announced that new gene expression data based on a validated method from TATAA Biocenter AB, which is significantly more sensitive than the pre-commercial method, shows that a larger proportion of patients, i.e. those with low ABCC3 expression, could have significant better effect of arfolitixorin than currently used prodrugs on PFS and ultimately on overall survival.

Opthea Limited, a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed patient dosing and all follow-up week 12 patient visits in the Company’s Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept for treatment of diabetic macular edema.

Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary endpoints, p=0.02, 0.035, and 0.031)

Athersys, Inc. announced that its partner in Japan, HEALIOS K.K., exercised in full its warrant to purchase shares of Athersys common stock.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced the appointment of Garry Nicholson to its board of directors.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it is launching a collaboration with the University of Alabama at Birmingham on the development of its single-dose, intranasal COVID-19 vaccine, named AdCOVID.

Joint Venture Procures from Established Manufacturers with Reliable Supply and Logistics for US Medical Operations